Cargando…

Overcoming multiple drug resistance mechanisms in medulloblastoma

INTRODUCTION: Medulloblastoma (MB) is the most common malignant paediatric brain tumour. Recurrence and progression of disease occurs in 15-20% of standard risk and 30-40% of high risk patients. We analysed whether circumvention of chemoresistance pathways (drug export, DNA repair and apoptotic inhi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Othman, Ramadhan T, Kimishi, Ioanna, Bradshaw, Tracey D, Storer, Lisa CD, Korshunov, Andrey, Pfister, Stefan M, Grundy, Richard G, Kerr, Ian D, Coyle, Beth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229867/ https://www.ncbi.nlm.nih.gov/pubmed/24887326 http://dx.doi.org/10.1186/2051-5960-2-57

Ejemplares similares

ABCB1 inhibition provides a novel therapeutic target to block TWIST1-induced migration in medulloblastoma
por: Nasir, Aishah, et al.
Publicado: (2021)

Corrigendum to: ABCB1 inhibition provides a novel therapeutic target to block TWIST1-induced migration in medulloblastoma
por: Nasir, Aishah, et al.
Publicado: (2021)

Update on molecular and genetic alterations in adult medulloblastoma
por: Kool, Marcel, et al.
Publicado: (2012)

MBRS-42. YB-1 - A NOVEL THERAPEUTIC TARGET IN HIGH-RISK MEDULLOBLASTOMA?
por: Taylor, Louisa, et al.
Publicado: (2020)

MBRS-45. TWIST1 AND ABCB1 ARE FUNCTIONAL DETERMINANTS OF METASTASIS IN MEDULLOBLASTOMA
por: Cardall, Alice, et al.
Publicado: (2020)

MEDB-64. Are Rab GTPases metastatic drivers in metastatic medulloblastoma?
por: Entwistle, Susannah, et al.
Publicado: (2022)

MBRS-27. EXOSOMES CARRY DISTINCT miRNAs THAT DRIVE MEDULLOBLASTOMA PROGRESSION
por: Jackson, Hannah K, et al.
Publicado: (2020)

Extracellular Vesicles Potentiate Medulloblastoma Metastasis in an EMMPRIN and MMP-2 Dependent Manner
por: Jackson, Hannah K., et al.
Publicado: (2023)

MBRS-28. EXOSOMES DRIVE MEDULLOBLASTOMA METASTASIS IN A MMP2 AND EMMPRIN DEPENDENT MANNER
por: Jackson, Hannah K, et al.
Publicado: (2020)

In search of effective therapies to overcome resistance to Temozolomide in brain tumours
por: Bouzinab, Kaouthar, et al.
Publicado: (2019)

Molecular subgroups of medulloblastoma: the current consensus
por: Taylor, Michael D., et al.
Publicado: (2011)

Hedgehog-mediated regulation of PPARγ controls metabolic patterns in neural precursors and shh-driven medulloblastoma
por: Bhatia, Bobby, et al.
Publicado: (2012)

MEDB-25. Do extracellular vesicles transfer a multidrug resistant phenotype via ABC transporters in medulloblastoma?
por: Wade, Philippa, et al.
Publicado: (2022)

Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma
por: Chan, Tiffany S Y, et al.
Publicado: (2021)

Identification of CD24 as a marker of Patched1 deleted medulloblastoma-initiating neural progenitor cells
por: Robson, Jonathan P., et al.
Publicado: (2019)

A role for ABCB1 in prognosis, invasion and drug resistance in ependymoma
por: Sabnis, Durgagauri H., et al.
Publicado: (2019)

MEDB-60. Medulloblastoma with extensive nodularity mimics cerebellar development and differentiates along the granular precursor lineage
por: Ghasemi, David R, et al.
Publicado: (2022)

3D hydrogels reveal medulloblastoma subgroup differences and identify extracellular matrix subtypes that predict patient outcome
por: Linke, Franziska, et al.
Publicado: (2020)

Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses
por: Okonechnikov, Konstantin, et al.
Publicado: (2023)

Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells
por: Kawauchi, D, et al.
Publicado: (2017)

Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature
por: Taylor, Louisa, et al.
Publicado: (2023)

Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples
por: Northcott, Paul A., et al.
Publicado: (2011)

Assessment of Cannabidiol and Δ9-Tetrahydrocannabiol in Mouse Models of Medulloblastoma and Ependymoma
por: Andradas, Clara, et al.
Publicado: (2021)

Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression
por: Korshunov, Andrey, et al.
Publicado: (2022)

Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
por: Ecker, Jonas, et al.
Publicado: (2015)

MBCL-08. INTEGRATIVE MOLECULAR ANALYSIS OF PATIENT-MATCHED DIAGNOSTIC AND RELAPSED MEDULLOBLASTOMAS
por: Kumar, Rahul, et al.
Publicado: (2020)

Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma
por: Krausert, Sonja, et al.
Publicado: (2022)

Pediatric brain tumor cancer stem cells: cell cycle dynamics, DNA repair, and etoposide extrusion
por: Hussein, Deema, et al.
Publicado: (2011)

FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma
por: Suryo Rahmanto, Aldwin, et al.
Publicado: (2016)

MBRS-68. SINGLE NUCLEUS RNA-SEQUENCING DECIPHERS INTRATUMORAL HETEROGENEITY IN MEDULLOBLASTOMA WITH EXTENSIVE NODULARITY (MBEN)
por: Ghasemi, David N, et al.
Publicado: (2020)

Activation of AMPK sensitizes medulloblastoma to Vismodegib and overcomes Vismodegib‐resistance
por: Gampala, Silpa, et al.
Publicado: (2021)

Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastoma
por: Eisemann, Tanja, et al.
Publicado: (2022)

Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas
por: Kool, Marcel, et al.
Publicado: (2012)

EMBR-21. CLINICALLY TRACTABLE OUTCOME PREDICTION OF GROUP 3/4 MEDULLOBLASTOMA BASED ON TPD52 IMMUNOHISTOCHEMISTRY: A MULTICOHORT STUDY
por: Delaidelli, Alberto, et al.
Publicado: (2021)

Medulloblastoma and ependymoma cells display increased levels of 5-carboxylcytosine and elevated TET1 expression
por: Ramsawhook, Ashley, et al.
Publicado: (2017)

PATH-03. Clinically Tractable Outcome Prediction of Group 3/4 Medulloblastoma Based on TPD52 Immunohistochemistry: a Multicohort Study
por: Delaidelli, Alberto, et al.
Publicado: (2022)

Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes
por: Sharma, Tanvi, et al.
Publicado: (2019)

Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays
por: Hovestadt, Volker, et al.
Publicado: (2013)

WNT/β-catenin pathway activation in Myc immortalised cerebellar progenitor cells inhibits neuronal differentiation and generates tumours resembling medulloblastoma
por: Rogers, H A, et al.
Publicado: (2012)

Clonal Selection Drives Genetic Divergence of Metastatic Medulloblastoma
por: Wu, Xiaochong, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2rthlec9bbqr8j48atm01qhb0l